Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).
ENPP1 is an ecto-nucleotide pyrophosphatase that plays an important role in purinergic signaling that regulates immune, cardiovascular, neurological, and hematological system functions.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Hematology | Immunotherapy | Neurology | Pharmaceuticals | Rare Diseases